메뉴 건너뛰기




Volumn 49, Issue 1, 2019, Pages 64-71

Corrigendum to: Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial): Luseogliflozin in T2DM with NAFLD (Hepatology Research, (2019), 49, 1, (64-71), 10.1111/hepr.13236);Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)

Author keywords

luseogliflozin; non alcoholic fatty liver disease; steatosis; type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; COLLAGEN TYPE 7; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUSEOGLIFLOZIN; TRIACYLGLYCEROL; URIC ACID;

EID: 85052796632     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.13406     Document Type: Erratum
Times cited : (89)

References (38)
  • 1
    • 84976479130 scopus 로고    scopus 로고
    • Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
    • Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73–84.
    • (2016) Hepatology , vol.64 , pp. 73-84
    • Younossi, Z.M.1    Koenig, A.B.2    Abdelatif, D.3    Fazel, Y.4    Henry, L.5    Wymer, M.6
  • 2
    • 0034831067 scopus 로고    scopus 로고
    • Nonalcoholic steatohepatitis
    • Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710–723.
    • (2001) Gastroenterology , vol.121 , pp. 710-723
    • Reid, A.E.1
  • 3
    • 79960029926 scopus 로고    scopus 로고
    • Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
    • Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–285.
    • (2011) Aliment Pharmacol Ther , vol.34 , pp. 274-285
    • Vernon, G.1    Baranova, A.2    Younossi, Z.M.3
  • 4
    • 84926643436 scopus 로고    scopus 로고
    • Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients
    • Nakahara T, Hyogo H, Yoneda M et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol 2014; 49: 1477–1484.
    • (2014) J Gastroenterol , vol.49 , pp. 1477-1484
    • Nakahara, T.1    Hyogo, H.2    Yoneda, M.3
  • 5
    • 85007162511 scopus 로고    scopus 로고
    • Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression
    • Seko Y, Sumida Y, Tanaka S et al. Development of hepatocellular carcinoma in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: association between PNPLA3 genotype and hepatocarcinogenesis/fibrosis progression. Hepatol Res 2017; 47: 1083–1092.
    • (2017) Hepatol Res , vol.47 , pp. 1083-1092
    • Seko, Y.1    Sumida, Y.2    Tanaka, S.3
  • 6
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
    • (2015) N Engl J Med , vol.373 , pp. 2117-2128
    • Zinman, B.1    Wanner, C.2    Lachin, J.M.3
  • 7
    • 85034766786 scopus 로고    scopus 로고
    • Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
    • (2017) N Engl J Med , vol.377 , pp. 644-657
    • Neal, B.1    Perkovic, V.2    Mahaffey, K.W.3
  • 8
    • 84947998361 scopus 로고    scopus 로고
    • Effect of canagliflozin on liver function tests in patients with type 2 diabetes
    • Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42: 25–32.
    • (2016) Diabetes Metab , vol.42 , pp. 25-32
    • Leiter, L.A.1    Forst, T.2    Polidori, D.3    Balis, D.A.4    Xie, J.5    Sha, S.6
  • 9
    • 85008262665 scopus 로고    scopus 로고
    • Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
    • Seko Y, Sumida Y, Tanaka S et al. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res 2017; 47: 1072–1078.
    • (2017) Hepatol Res , vol.47 , pp. 1072-1078
    • Seko, Y.1    Sumida, Y.2    Tanaka, S.3
  • 10
    • 85021699331 scopus 로고    scopus 로고
    • Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
    • Seko Y, Sumida Y, Sasaki K et al. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol 2018; 53: 140–151.
    • (2018) J Gastroenterol , vol.53 , pp. 140-151
    • Seko, Y.1    Sumida, Y.2    Sasaki, K.3
  • 11
    • 85028766250 scopus 로고    scopus 로고
    • Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study
    • Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 2017; 87: 13–19.
    • (2017) Curr Ther Res Clin Exp , vol.87 , pp. 13-19
    • Tobita, H.1    Sato, S.2    Miyake, T.3    Ishihara, S.4    Kinoshita, Y.5
  • 12
    • 85042524553 scopus 로고    scopus 로고
    • Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies
    • Akuta N, Watanabe C, Kawamura Y et al. Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies. Hepatol Commun 2017; 1: 46–52.
    • (2017) Hepatol Commun , vol.1 , pp. 46-52
    • Akuta, N.1    Watanabe, C.2    Kawamura, Y.3
  • 13
    • 85012306085 scopus 로고    scopus 로고
    • Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus
    • Sumida Y, Seko Y, Yoneda M, Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res 2017; 47: 266–280.
    • (2017) Hepatol Res , vol.47 , pp. 266-280
    • Sumida, Y.1    Seko, Y.2    Yoneda, M.3
  • 14
    • 85040734374 scopus 로고    scopus 로고
    • Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study
    • Shibuya T, Fushimi N, Kawai M et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab 2018; 20: 438–442.
    • (2018) Diabetes Obes Metab , vol.20 , pp. 438-442
    • Shibuya, T.1    Fushimi, N.2    Kawai, M.3
  • 16
    • 85033483636 scopus 로고    scopus 로고
    • Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis
    • Ito K, Murotani K, Nakade Y et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol 2017; 32: 1922–1930.
    • (2017) J Gastroenterol Hepatol , vol.32 , pp. 1922-1930
    • Ito, K.1    Murotani, K.2    Nakade, Y.3
  • 17
    • 84937252875 scopus 로고    scopus 로고
    • Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease
    • Abe M, Miyake T, Kuno A et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2015; 50: 776–784.
    • (2015) J Gastroenterol , vol.50 , pp. 776-784
    • Abe, M.1    Miyake, T.2    Kuno, A.3
  • 18
    • 70349546276 scopus 로고    scopus 로고
    • Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease
    • Shah AG, Lydecker A, Murray K et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104–1112.
    • (2009) Clin Gastroenterol Hepatol , vol.7 , pp. 1104-1112
    • Shah, A.G.1    Lydecker, A.2    Murray, K.3
  • 19
    • 84855390033 scopus 로고    scopus 로고
    • Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
    • Sumida Y, Yoneda M, Hyogo H et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012; 12: 2.
    • (2012) BMC Gastroenterol , vol.12 , pp. 2
    • Sumida, Y.1    Yoneda, M.2    Hyogo, H.3
  • 20
    • 85046628830 scopus 로고    scopus 로고
    • The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study
    • Ishiba H, Sumida Y, Tanaka S et al. The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol 2018. https://doi.org/10.1007/s00535-018-1474-y.
    • (2018) J Gastroenterol
    • Ishiba, H.1    Sumida, Y.2    Tanaka, S.3
  • 21
    • 34247384560 scopus 로고    scopus 로고
    • The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
    • Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846–854.
    • (2007) Hepatology , vol.45 , pp. 846-854
    • Angulo, P.1    Hui, J.M.2    Marchesini, G.3
  • 22
    • 84979780774 scopus 로고    scopus 로고
    • Hepatic fat quantification using the two-point Dixon method and fat color maps based on non-alcoholic fatty liver disease activity score
    • Hayashi T, Saitoh S, Takahashi J et al. Hepatic fat quantification using the two-point Dixon method and fat color maps based on non-alcoholic fatty liver disease activity score. Hepatol Res 2017; 47: 455–464.
    • (2017) Hepatol Res , vol.47 , pp. 455-464
    • Hayashi, T.1    Saitoh, S.2    Takahashi, J.3
  • 24
    • 79960266192 scopus 로고    scopus 로고
    • T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease
    • Pacifico L, Martino MD, Catalano C et al. T1-weighted dual-echo MRI for fat quantification in pediatric nonalcoholic fatty liver disease. World J Gastroenterol 2011; 17: 3012–3019.
    • (2011) World J Gastroenterol , vol.17 , pp. 3012-3019
    • Pacifico, L.1    Martino, M.D.2    Catalano, C.3
  • 25
    • 85031712678 scopus 로고    scopus 로고
    • The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium–glucose cotransporter 2 inhibitor ipragliflozin
    • Takeda A, Irahara A, Nakano A et al. The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium–glucose cotransporter 2 inhibitor ipragliflozin. Intern Med 2017; 56: 2739–2744.
    • (2017) Intern Med , vol.56 , pp. 2739-2744
    • Takeda, A.1    Irahara, A.2    Nakano, A.3
  • 26
    • 40449095940 scopus 로고    scopus 로고
    • Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL
    • Kim H, Taksali SE, Dufour S et al. Comparative MR study of hepatic fat quantification using single-voxel proton spectroscopy, two-point Dixon and three-point IDEAL. Magn Reson Med 2008; 59: 521–527.
    • (2008) Magn Reson Med , vol.59 , pp. 521-527
    • Kim, H.1    Taksali, S.E.2    Dufour, S.3
  • 27
    • 67649205135 scopus 로고    scopus 로고
    • Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered
    • McPherson S, Jonsson JR, Cowin GJ et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol 2009; 51: 389–397.
    • (2009) J Hepatol , vol.51 , pp. 389-397
    • McPherson, S.1    Jonsson, J.R.2    Cowin, G.J.3
  • 28
    • 77954757826 scopus 로고    scopus 로고
    • Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat signal separation in liver-fat quantification: comparison to liver biopsy
    • Fischer MA, Nanz D, Reiner CS et al. Diagnostic performance and accuracy of 3-D spoiled gradient-dual-echo MRI with water- and fat signal separation in liver-fat quantification: comparison to liver biopsy. Invest Radiol 2010; 45: 465–470.
    • (2010) Invest Radiol , vol.45 , pp. 465-470
    • Fischer, M.A.1    Nanz, D.2    Reiner, C.S.3
  • 29
    • 84865759802 scopus 로고    scopus 로고
    • Liver fat quantification by dual-echo MR imaging outperforms traditional histopathological analysis
    • Fischer MA, Raptis DA, Montani M et al. Liver fat quantification by dual-echo MR imaging outperforms traditional histopathological analysis. Acad Radiol 2012; 19: 1208–1214.
    • (2012) Acad Radiol , vol.19 , pp. 1208-1214
    • Fischer, M.A.1    Raptis, D.A.2    Montani, M.3
  • 31
    • 85052836880 scopus 로고    scopus 로고
    • Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)
    • Kuchay MS, Krishan S, Mishra SK et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 2018; 41: 1801–1808.
    • (2018) Diabetes Care , vol.41 , pp. 1801-1808
    • Kuchay, M.S.1    Krishan, S.2    Mishra, S.K.3
  • 32
    • 84155188801 scopus 로고    scopus 로고
    • Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease
    • Kowdley KV, Belt P, Wilson LA et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77–85.
    • (2012) Hepatology , vol.55 , pp. 77-85
    • Kowdley, K.V.1    Belt, P.2    Wilson, L.A.3
  • 33
    • 79954442712 scopus 로고    scopus 로고
    • A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease
    • Sumida Y, Yoneda M, Hyogo H et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257–268.
    • (2011) J Gastroenterol , vol.46 , pp. 257-268
    • Sumida, Y.1    Yoneda, M.2    Hyogo, H.3
  • 34
    • 84945436270 scopus 로고    scopus 로고
    • Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients
    • Seko Y, Sumida Y, Tanaka S et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 2015; 45: E53–E61.
    • (2015) Hepatol Res , vol.45 , pp. E53-E61
    • Seko, Y.1    Sumida, Y.2    Tanaka, S.3
  • 35
    • 85038094859 scopus 로고    scopus 로고
    • Current and future pharmacological therapies for NAFLD/NASH
    • Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 2018; 53: 362–376.
    • (2018) J Gastroenterol , vol.53 , pp. 362-376
    • Sumida, Y.1    Yoneda, M.2
  • 36
    • 84947786115 scopus 로고    scopus 로고
    • Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus
    • Qiang S, Nakatsu Y, Seno Y et al. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus. Diabetol Metab Syndr 2015; 7: 104.
    • (2015) Diabetol Metab Syndr , vol.7 , pp. 104
    • Qiang, S.1    Nakatsu, Y.2    Seno, Y.3
  • 37
    • 85028772096 scopus 로고    scopus 로고
    • Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild/moderate hepatic impairment: a pharmacokinetic study
    • Samukawa Y, Sata M, Furihata K et al. Luseogliflozin, an SGLT2 inhibitor, in Japanese patients with mild/moderate hepatic impairment: a pharmacokinetic study. Clin Pharmacol Drug Dev 2017; 6: 439–447.
    • (2017) Clin Pharmacol Drug Dev , vol.6 , pp. 439-447
    • Samukawa, Y.1    Sata, M.2    Furihata, K.3
  • 38
    • 84903557735 scopus 로고    scopus 로고
    • Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study
    • Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin 2014; 30: 1245–1255.
    • (2014) Curr Med Res Opin , vol.30 , pp. 1245-1255
    • Seino, Y.1    Sasaki, T.2    Fukatsu, A.3    Ubukata, M.4    Sakai, S.5    Samukawa, Y.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.